Vera Therapeutics Inc

Company Profile

Vera Therapeutics Inc had its IPO on 2021-05-14 under the ticker symbol VERA.

The company operates in the Healthcare sector and Biotechnology industry. Vera Therapeutics Inc has a staff strength of 49 employees.

Stock update

Shares of Vera Therapeutics Inc opened at $18.98 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $17.9 - $19.42, and closed at $17.94.

This is a -5.58% slip from the previous day's closing price.

A total volume of 323,253 shares were traded at the close of the day’s session.

In the last one week, shares of Vera Therapeutics Inc have slipped by -3.24%.

Vera Therapeutics Inc's Key Ratios

Vera Therapeutics Inc has a market cap of $821.66 million, indicating a price to book ratio of 4.3088 and a price to sales ratio of 0.

In the last 12-months Vera Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-90727000. The EBITDA ratio measures Vera Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Vera Therapeutics Inc’s operating margin was 0% while its return on assets stood at -40.72% with a return of equity of -81.94%.

In Q2, Vera Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Vera Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-3.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vera Therapeutics Inc’s profitability.

Vera Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -4.8579. Its price to sales ratio in the trailing 12-months stood at 0.

Vera Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$195.18 million

Total Liabilities

$26.84 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Vera Therapeutics Inc ended 2024 with $195.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $195.18 million while shareholder equity stood at $140.52 million.

Vera Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $26.84 million in other current liabilities, 44000.00 in common stock, $-263343000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.89 million and cash and short-term investments were $181.02 million. The company’s total short-term debt was $2,560,000 while long-term debt stood at $24.96 million.

Vera Therapeutics Inc’s total current assets stands at $190.61 million while long-term investments were $29000.00 and short-term investments were $147.13 million. Its net receivables were $0 compared to accounts payable of $13.28 million and inventory worth $0.

In 2024, Vera Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Vera Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$17.94

52-Week High

$23.39

52-Week Low

$5.2

Analyst Target Price

$14.6

Vera Therapeutics Inc stock is currently trading at $17.94 per share. It touched a 52-week high of $23.39 and a 52-week low of $23.39. Analysts tracking the stock have a 12-month average target price of $14.6.

Its 50-day moving average was $17.57 and 200-day moving average was $11.92 The short ratio stood at 8.12 indicating a short percent outstanding of 0%.

Around 734.9% of the company’s stock are held by insiders while 9709.2% are held by institutions.